Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human δ-opioid receptor with an inverse agonist

Molecular Pharmacology

Volumn 67, Issue 1, 2005, Pages 336-348

  Piñeyro, Graciela ^a,c   Azzi, Mounia ^a   Deléan, André ^a   Schiller, Peter W ^b   Bouvier, Michel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; BREMAZOCINE; CYCLIC AMP; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; TYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINEPHENYLALANYLPHENYLALANYL HYDROXIDE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MODEL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 11244352269     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.004549     Document Type: Article

References (44)

1. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
2. Benovic JL, Regan JW, Matsui H, Mayor F Jr, Cotecchia S, Leeb-Lundberg LM, Caron MG, and Lefkowitz RJ (1987) Agonist-dependent phosphorylation of the α2-adrenergic receptor by the β-adrenergic receptor kinase. J Biol Chem 262:17251-17253.
3. Berg KA, Stout BD, Cropper JD, Maayani S, and Clarke WP (1999) Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 55:863-872.
4. Blaukat A, Micke P, Kalatskaya I, Faussner A, and Muller-Esterl W (2003) Down-regulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure. Am J Physiol 284:H1909-H1916.
5. Bouaboula M, Dussossoy D, and Casellas P (1999) Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 274:20397-20405.
6. Chau LY, Peck K, Yen HH, and Wang JY (1994) Agonist-induced down-regulation of platelet-activating factor receptor gene expression in U937 cells. Biochem J 301:911-916.
7. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
8. Chidiac P, Nouet S, and Bouvier M (1996) Agonist-induced modulation of inverse agonist efficacy at the β2-adrenergic receptor. Mol Pharmacol 50:662-669.
9. Costa T, Ogino Y, Munson PJ, Onaran HO, and Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41:549-560.
10. De Lean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108-7117.
11. De Vries L, Zheng B, Fischer T, Elenko E, and Farquhar MG (2000) The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 40:235-271.
12. Elenko E, Fischer T, Niesman I, Harding T, McQuistan T, Von Zastrow M, and Farquhar MG (2003) Spatial regulation of Gαi protein signaling in clathrin-coated membrane microdomains containing GAIP. Mol Pharmacol 64:11-20.
13. Fathy DB, Leeb T, Mathis SA, and Leeb-Lundberg LM (1999) Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. Effect of basal desensitization. J Biol Chem 274:29603-29606.
14. Fitzsimons CP, Monczor F, Fernandez N, Shayo C, and Davio CA (2004) Mepyramine, a histamine H1 receptor inverse agonist, binds preferentially to a G protein coupled form of the receptor and sequesters G protein. J Biol Chem 279:34431-34439.
15. Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, et al. (2003) Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100:11086-11091.
16. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J Biol Chem 276:24433-24436.
17. Heinflink M, Nussenzveig DR, Grimberg H, Lupu-Meiri M, Oron Y, and Gershengorn MC (1995) A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Mol Endocrinol 9:1455-1460.
18. Kenakin T (1997a) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
19. Kenakin T (1997b) Efficacy, in Pharmacologic Analysis of Drug-Receptor Interaction, pp 289-330, Lippincott-Raven, Philadelphia.
20. Kenakin T (2004) Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
21. Kouhen OM, Wang G, Solberg J, Erickson LJ, Law PY, and Loh HH (2000) Hierarchical phosphorylation of δ-opioid receptor regulates agonist-induced receptor desensitization and internalization. J Biol Chem 275:36659-36664.
22. Law PY, Kouhen OM, Solberg J, Wang W, Erickson LJ, and Loh HH (2000) Deltorphin II-induced rapid desensitization of δ-opioid receptor requires both phosphorylation and internalization of the receptor. J Biol Chem 275:32057-32065.
23. Lee TW, Cotecchia S, and Milligan G (1997) Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoreceptor by ligands that act as inverse agonists. Biochem J 325:733-739.
24. Lee TW, Sole MJ, and Wells JW (1986) Assessment of a ternary model for the binding of agonists to neurohumoral receptors. Biochemistry 25:7009-7020.
25. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
26. Lohse MJ, Benovic JL, Caron MG, and Lefkowitz RJ (1990) Multiple pathways of rapid β2-adrenergic receptor desensitization. Delineation with specific inhibitors. J Biol Chem 265:3202-3211.
27. MacEwan DJ and Milligan G (1996) Inverse agonist-induced up-regulation of the human β2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 50:1479-1486.
28. Marie J, Koch C, Pruneau D, Paquet JL, Groblewski T, Larguier R, lombard C, Deslauriers B, Maigret B, and Bonnafous JC (1999) Constitutive activation of the human bradykinin B2 receptor indiced by mutations in transmembrane helices III and VI. Mol Pharmacol 55:92-101.
29. oα. J Neurochem 76:1805-1813.
30. Petaja-Repo UE, Hogue M, Laperrière A, Bhalla S, Walker P, and Bouvier M (2001) Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J Biol Chem 276:4416-4423.
31. Petaja-Repo UE, Hogue M, Laperriere A, Walker P, and Bouvier M (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human δ opioid receptor. J Biol Chem 275:13727-13736.
32. Pineyro G, Azzi M, De Lean A, Schiller P, and Bouvier M (2001) Short-term inverse-agonist treatment induces reciprocal changes in δ-opioid agonist and inverse-agonist binding capacity. Mol Pharmacol 60:816-827.
33. Ransnas LA, Svoboda P, Jasper JR, and Insel PA (1989) Stimulation of β-adrenergic receptors of S49 lymphoma cells redistributes the a subunit of the stimulatory G protein between cytosol and membranes. Proc Natl Acad Sci USA 86:7900-7903.
34. Samama P, Bond RA, Rockman HA, Milano CA, and Lefkowitz RJ (1997) Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc Natl Acad Sci USA 94:137-141.
35. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
36. Schiller P, Weltrowska G, Berezowska I, Nguyen T, Wilkes B, Lemieux C, and Chung N (1999) The TIPP opioid peptide family: development of delta antagonists, delta agonists and mixed mu agonist/delta antagonists. Biopolymers 51:411-425.
37. Shah BH, MacEwan DJ, and Milligan G (1995) Gonadotrophin-releasing hormone receptor agonist-mediated down-regulation of Gq alpha/G11α (pertussis toxin-insensitive) G proteins in αT3-1 gonadotroph cells reflects increased G protein turnover but not alterations in mRNA levels. Proc Natl Acad Sci USA 92:1886-1890.
38. Tsao PI and von Zastrow M (2000) Type-specific sorting of G protein-coupled receptors after endocytosis. J Biol Chem 275:11130-11140.
39. Valiquette M, Bonin H, Hnatowich M, Caron MG, Lefkowitz RJ, and Bouvier M (1990) Involvement of tyrosine residues located in the carboxyl tail of the human β2-adrenergic receptor in agonist-induced down-regulation of the receptor. Proc Natl Acad Sci USA 87:5089-5093.
40. Valiquette M, Vu HK, Yue SY, Wahlestedt C, and Walker P (1996) Involvement of Trp-284, Val-296, and Val-297 of the human δ-opioid receptor in binding of δ-selective ligands. J Biol Chem 271:18789-18796.
41. von Zastrow M (2003) Mechanisms regulating membrane trafficking of G protein-coupled receptors in the endocytic pathway. Life Sci 74:217-224.
42. Wedegaertner PB, Bourne HR, and von Zastrow M (1996) Activation-induced subcellular redistribution of Gs alpha. Mol Biol Cell 7:1225-1233.
43. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996) The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J Theor Biol 181:381-397.
44. Yang Q and Lanier SM (1999) Influence of G protein type on agonist efficacy. Mol Pharmacol 56:651-656.